Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Downregulation of ERBB4 leads to peripartum cardiomyopathy

July 6, 2021

Vivavision Biotechnology describes new ROCK2 inhibitors

July 6, 2021

Model of diastolic dysfunction with preserved ejection fraction developed to test HDAC6 inhibition

July 6, 2021

Alnylam initiates phase II study of zilebesiran for mild to moderate hypertension

June 30, 2021

Loss-of-function mutations in IPO8 lead to syndromic thoracic aortic aneurysm

June 30, 2021

First patients enrolled in IMPROVE-DiCE study of IMB-101

June 23, 2021

Sirtuin affects cardiac lipotoxicity via secondary mechanism

June 15, 2021

IMDC recommends continuation of phase IIb study of nangibotide in septic shock

June 10, 2021

InCarda announces progress in development program for InRhythm

June 10, 2021

Arena begins phase II study of temanogrel for coronary microvascular obstruction

June 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...